With the accelerated approval of Brigatinib, and now three approved ALK inhibitors in the 2nd-line setting, how do you decide between these agents?  

Should we be routinely sequencing ALK to select an ALK inhibitor with the appropriate efficacy, matched to resistance patterns?



Answer from: Medical Oncologist at Academic Institution